IMA-402 is under clinical development by Immatics and currently in Phase II for Lung Cancer. According to GlobalData, Phase II drugs for Lung Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMA-402’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMA-402 overview

IMA-402 is under development for the treatment of solid tumors, uveal melanoma, ovarian cancer, lung cancer, uterine cancer and synovial sarcoma. The therapeutic candidate is soluble bi-specific fusion protein. The drug candidate is being developed based on XPRESIDENT and Bispecific T-Cell Receptor (TCR) platform technology. It is administered through intravenous route. It acts by targeting cancer testis antigen (CTA).

It was also under development for hematological tumors.

Immatics overview

Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. The company is headquartered in Tubingen, Baden-Wurttemberg, Germany.

For a complete picture of IMA-402’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.